Qu Biologics has added Karn Manhas, Founder and CEO of Terramera, to its Board of Directors.
Qu Biologics is a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function.
Manhas brings a wealth of experience and knowledge in government, business development and as a clean technology entrepreneur to Qu Biologics’ Board of Directors.
After earning a degree in Biology and Biotechnology from McGill University, Karn was elected B.C.’s youngest Member of the Legislative Assembly (MLA) at age 24, after which he obtained his law degree from the University of British Columbia and founded Terramera, a Vancouver-based agtech company transforming the way food is grown and the economics of agriculture.
RELATED: How Can BC Tech Turn Our COVID Crisis Into Opportunity?
Under Karn’s leadership, Terramera has raised more than $82 million in equity funding to execute that vision and scale its proprietary technology, achieving multiple licensing partnerships and accelerated growth.
“Qu Biologics’ Board of Directors is very pleased to welcome Karn,” affirmed Dr. Hal Gunn, Qu Biologics’ CEO. “Karn is a remarkable young leader. There are many parallels between Terramera’s vision for transforming plant health and Qu Biologics’ vision for transforming human health. We are very much looking forward to working together to finance, build, scale and execute Qu’s vision.”